key: cord-0813177-4g70j22b authors: She, Jiatong; Liu, lanqin; Liu, Wenjun title: Providing children with COVID‐19 vaccinations is challenging due to lack of data and wide‐ranging parental acceptance date: 2021-10-28 journal: Acta Paediatr DOI: 10.1111/apa.16137 sha: 20c00699206c1aeb97374e1f4673c93fec9371c7 doc_id: 813177 cord_uid: 4g70j22b AIM: Vaccines are vital to ending the COVID‐19 pandemic and we reviewed the data on vaccinating children, and including them in clinical trials, as most of the activity has focused on adults. METHODS: English and Chinese databases, including PubMed, Elsevier Scopus, Web of Science, CNKI and CQVIP were searched, along with websites such as the World Health Organization and the University of Oxford. RESULTS: We identified 44 papers and 16 news items about vaccinating children against the virus, published from 10 February 2020 to 14 July 2021. Child vaccination has been slow and only a few countries have included children in Phase II or III clinical trials. The data on children were much more limited than on adults, but most children were asymptomatic or had mild symptoms and some deaths had been recorded. More clinical trials are needed to assess the safety and efficacy of vaccinating children, as higher vaccination levels can help to build up herd immunity. The percentage of parents willing to vaccinate their children against the virus ranged from 48.2% to 72.6%, with much lower rates for letting them participate in clinical trials. CONCLUSION: Vaccines should be offered to children as soon as their safety and efficacy are established. infection is still a matter of global concern. 1,3 This is due to huge differences in factors such as people's values, cultures, traditions, mobility and disease control measures, and how intensely they are implemented. In general, diagnoses, fatalities and immunity levels have been low in children, but they have proved highly infectious and the transmission route has been relatively wide. SARS-CoV-2 endangers public health safety, damages the physical health of infected children and affects their psychological and spiritual health. 4 Measures such as nucleic acid testing, quarantining and wearing masks can effectively curb the spread of the virus in the short term. However, in the long run, vaccination is the way for the population to obtain specific immunity to the virus and is the most effective way to prevent the spread of the virus. 3 • This review focused on the challenges of vaccinating children to reduce COVID-19, as most of the activity has focused on adults. • We identified 60 papers and news item from leading databases and websites up to 14 July 2021 and these showed limited paediatric involvement in clinical trials and wide variations in parental support for vaccinations. • Child vaccination should be offered as soon as its safety and efficacy are established. Studies have also showed that, although most children have had mild COVID-19, there have also been many severe cases. According 12 Ng et al. found that 5.3% of 302 adults who were not infected with SARS-CoV-2 carried immunoglobulin G antibodies that could bind to the virus. However, protein reactive immunoglobulin G antibodies could not be detected in 43.8% of the 48 who were virus free. 13 A Canadian study that analysed data from more than 200,000 COVID-19 cases, and was published in July 2021, reported that the Alpha, Beta and Gamma variants were associated with a greater surge in virulence and transmissibility than non-variants of concern. 14 These variants also increased the risk of hospitalisation, intensive care admissions and death by 59%, 105% and 61% respectively. They also increased the probability of children being Therefore, children should be vaccinated against COVID-19 to prevent the pandemic from harming children, families and society. The global COVID-19 vaccine development is based on seven key technical vaccine routes: inactivated, virus-like particle, protein subunit, virus-vectored, deoxyribonucleic acid, messenger ribonucleic acid and live-attenuated. Most of the current vaccines target the spike protein, glycoprotein S, and its variants. 16 The structure and function of SARS-CoV-2 glycoprotein S are similar to highly pathogenic Beta coronaviruses, such as Middle East respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. Glycoprotein S comprises two subunits. S1 contains a receptor binding domain that interacts with the angiotensin-converting enzyme 2 receptor on the cell surface. S2 mediates the fusion of the virus membrane and cell membrane by forming a six-helix bundle fusion core. In order to prevent SARS-CoV-2 infections, it is very important to form neutralising antibodies against the S1 receptor binding domain and the S1 N-terminal domain. These antibodies can block the bind- a few people were left with impaired heart muscle, so the benefits of vaccination clearly outweigh the risks. 30 Some adults have experienced adverse events or even serious adverse events after vaccination and more clinical safety assessments are needed before children are fully vaccinated. On 20 April 2021, the WHO stated that three main variants of SARS-CoV-2 had emerged. The Alpha variant had been reported in 125 countries by that date. There was no difference in the neutral response of the recovered plasma in this strain and the initial SARS-CoV-2 strain, so it did not affect the efficacy of the existing vaccine. 32 The Beta variant had been found in 67 countries by that date and has been associated with a higher viral load that might increase infectivity. 32 was mainly limited to the immunoglobulin G anti-S antibody and the overall level of neutralising activity was lower than adults. 35 The efficacy of existing vaccines needs to be further studied, as variants have been discovered in many countries, leading to a further increase in the number of infections. Table 3) Savulescu et al. reported that the fatality rate for influenza in the UK and USA was more than one per 1,000,000 if children were not vaccinated and less than one per 25,000,000 if they were. 20 The key findings of this review were that data on children COVID-19 vaccination were limited, as most of the activity has focused on adults. More clinical trials are needed to assess the safety and efficacy of vaccinating children, as higher vaccination levels can help to build up herd immunity. However, there are wide variations in the percentage of parents who would be willing to have their children vaccinated. Furthermore, we still do not know the full impact that the COVID-19 pandemic will have on children's lives and learning, public health safety and their parents' ability to work and support the economy. However, there is no doubt that the consequences will be felt many years to come. Therefore, protecting children from the SARS-CoV-2 infection is both a moral obligation and a practical need. If the vaccine is safe and effective for children, then it should be provided as soon as possible. The authors have no conflicts of interest to declare. COVID-19 epidemic: Disease characteristics in children Estimating infectiousness throughout SARS-CoV-2 infection course One Hundred days of coronavirus disease 2019 prevention and control in China State Data Report. 2021. Accessed COVAX Facility convenes first meeting of COVAX AMC engagement group Epidemiology of COVID-19 infection in young children under five years: A systematic review and meta-analysis Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study Stepwise school opening and an impact on the epidemiology of COVID-19 in the children Multisystem inflammatory syndrome in U.S. children and adolescents The United States Centers for Disease Control and Prevention. Health Department-Reported Cases of Multisystem Inflammatory Syndrome in Children (MIS-C) in the United States Preliminary evidence on long COVID in children Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19 Preexisting and de novo humoral immunity to SARS-CoV-2 in humans Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in Ontario Warp speed for COVID-19 vaccines: Why are children stuck in neutral? Evolution of the COVID-19 vaccine development landscape Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia Summary of data publicly reported by the Centers for Disease Control and Prevention Global ethical considerations regarding mandatory vaccination in children Is Israel close to herd immunity? Experts: Vaccination of children is a priority for the future Oxford coronavirus vaccine children's study-FAQs Chinese COVID-19 Vaccine Efficacy Better than Expected Interview with Mr Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial AAP recommends COVID-19 vaccines for eligible teens Perinatal SARS-CoV-2 infection and neonatal COVID-19: A 2021 update Covid-19: Pfizer reports 100% vaccine efficacy in children aged 12 to 15 Efficacy and safety of COVID-19 vaccines: a systematic review Evaluation of safety of two inactivated COVID-19 vaccines in a large-scale emergency use Covid-19: Should we be worried about reports of myocarditis and pericarditis after mRNA vaccines? Myocarditis with COVID-19 mRNA vaccines World Health Organization. COVID-19 Weekly Epidemiological Update mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study Dynamic surveillance of SARS-CoV-2 shedding and neutralizing antibody in children with COVID-19 Parents' and guardians' views on the acceptability of a future COVID-19 vaccine: A multi-methods study in England Caregiver willingness to vaccinate their children against COVID-19: Cross sectional survey Parental Acceptability of COVID-19 vaccination for children under the age of 18 years: cross-sectional online survey COVID-19: Parent and caregiver concerns about reopening New Zealand schools Evaluation of COVID-19 vaccine refusal in parents Factors associated with parents' willingness to enroll their children in trials for COVID-19 vaccination Global surge in measles and major international survey reinforce the need for greater awareness and uptake of all vaccinations Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study Early estimates of the indirect effects of the COVID-19 pandemic on maternal and child mortality in low-income and middle-income countries: a modelling study After COVID-19, a future for the world's children? Children are unlikely to be the main drivers of the COVID-19 pandemic -A systematic review The importance of advancing SARS-CoV-2 vaccines in children Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination Five reasons why COVID herd immunity is probably impossible covid -19-data-and-stati stics/ covid -19-case-demog raphi cs#age-gender 52. Epidemiology Working Group for Ncip Epidemic Response CCfDC, Prevention Mini-review discussing the reliability and efficiency of COVID-19 vaccines Safety and immunogenicity of a recombinant tandem-repeat dimeric receptor binding domain-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials Lancet Infect Dis Acute allergic reactions to mRNA COVID-19 vaccines Reactogenicity following receipt of mRNA-based COVID-19 vaccines The COVID-19 vaccine race-weekly update China's vaccination rate is expected to reach 40%, a report on the approval of many new coronavirus vaccine Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: The PROFISCOV Study Providing children with COVID-19 vaccinations is challenging due to lack of data and wide-ranging parental acceptance